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Abstract Despite the great enthusiasm about tissue
engineering during the 1980s and the many significant
basic observations made since then, the clinical application
of tissue-engineered products has been limited. However,
the prospect of creating new human tissues and organs is
still exciting and continues to be a significant challenge for
scientists and clinicians. A human arm is an extremely
complicated biological construction. Considering regrow-
ing a human arm requires asking about the current state-of-
the-art of tissue engineering and the real capabilities that it
may offer within a realistic time horizon. This work briefly
addresses the state-of-the-art in the fields of cells and
scaffolds that have high regenerative potential. Additional
tools that are required to reconstruct more complex parts of
the body, such as a human arm, seem achievable with the
already available more sophisticated culture systems
including three-dimensional organization, dynamic condi-
tions and co-cultures. Finally, we present results on cell
differentiation and cell and tissue maturation in culture
when cells are exposed to mechanical forces. We postulate
that in the foreseeable future even such complicated
structures such as a human arm will be regrown in full
in vitro under the conditions of a mechanically controlled
co-culture system.
1 Introduction
Responding to Joachim Kohn’s challenge to consider the
ability of regrowing a human arm, we naturally turned to
regenerative medicine. According to the most concise
description given by Mason, ‘‘regenerative medicine
replaces or regenerates human cells, tissue or organs to
restore or establish normal function’’ [1]. The concept we
propose is based on the possibility of obtaining ex vivo a
functional construction, which mimics both the appearance
and function of a human limb. It would consist of a tem-
porary scaffold and the patient’s own biological material.
Our optimism is based on the opportunities offered by
modern tissue engineering (TE). Already 15 years ago,
McCarthy cited Robert Langer: ‘‘…Tissue engineering is at
the stage that genetic engineering was at in 1981—no
products approved, but some on the horizon. It is a
potentially explosive area…’’ [2]. To the disappointment of
many of us, the current number of clinical applications of
TE products is still modest.
The majority of TE products have been introduced on
the medical market in the United States of America
(USA) [3]. In the European Union (EU), the appropriate
approval procedure was regulated only at the end of 2008
[4]. This new policy may open new possibilities, although
TE products have been classified in the EU as medicinal
products and as such are subject to a costly and time
consuming approval procedure. At the same time, sig-
nificant scientific progress is being made in all fields that
contribute to regenerative medicine: stem cell research,
sophisticated scaffolds for cell manipulation and trans-
plantation, and complex co-culture systems in vitro. In
this paper, we present a brief review of the key areas of
progress that bring us closer to successfully regrowing a
human arm.
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2 From replacement to regeneration
The question—can we or can we not regrow a human
arm?—came at a moment when, after years of investiga-
tions, biomaterials have been successfully implemented in
the clinical setting as replacements for various tissues.
During the last two decades, biomaterial scaffolds
especially designed for TE applications have been pro-
posed [5]. Interestingly, although a huge variety of syn-
thetic implantable materials is available, the majority of TE
products on the medical market are based on the scaffolds
of natural origin (Table 1). This indicates that the real
expansion of sophisticated man-made scaffolds approved
for TE applications is still to come. There are other factors
that justify this expectation. The number of publications
found in the pubmed database up to March 2010 was five
times higher for ‘‘bone TE’’ as compared to ‘‘skin TE’’,
while the relation between the TE products on the market
was reversed (Table 1). At the same time, the peak of
patents in bone TE in the 1985–2010 was noted in 2002
while the growing trend for publications in this field per-
sists [6]. This would confirm the patent-publication-market
approval order.
Another important issue is a growing interest in under-
standing cell-material interactions [7]. Thus, in a short time
we may have the benefit of not only cell tolerating mate-
rials, but potentially also cell-instructive materials, which
opens new possibilities for advanced ex vivo creation of
replacement tissues.
3 Cells as the main players
Cell-based concepts for regenerative medicine became
possible as a result of availability of cells—successfully
manipulated in vitro—with the capability to make tissue.
The choice of cell source and cell type(s) is critical to
success. In brief, initially, lineage-committed cells
Table 1 TE products currently available on the medical market
Intended use Product name (Company) Cell type used Scaffold/material used
Wound healing, burns,
diabetic and venous leg
ulcers
Dermagraft (Shire regenerative
medicine, st Helier, Jersey)





Type I bovine collagen matrix
MySkin (Altrika Ltd, Sheffield,
UK)
Autologous keratinocytes Silicone coated with a chemically
controlled plasma polymer film
OrCell (Forticell Bioscience,
Englewood Cliffs, NJ, USA)
Allogenic fibroblasts and
layer of keratinocytes
Type I bovine collagen sponge





A compound of polyethyleneoxide
terephthalate and polybutylene
terephthalate
Cartilage defects Hyalograft 3D (Fidia Farmaceutici
s.p.a.)








Autologous chondrocytes Rat collagen type I
J-tec, Japan Tissue Engineering Co Autologous chondrocytes Atelocollagen gel
Novocart Inject Novocart 3D
(Melsungen, Germany)
Autologous chondrocytes Polymerizable hydrogel Collagen type I





and bovine collagen granules




















Autologous bone marrow aspirate
a As an option
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harvested from the tissues were considered the major cell
type for TE applications. Chondrocytes were among the
first cells pursued in the field of TE [8]. Green demon-
strated successful rabbit knee cartilage regeneration by
chondrocytes seeded on demineralized bone. Soon after,
Burke et al. [9] generated the first tissue engineered skin
using a collagen matrix and dermal fibroblasts, followed by
successful generation of epidermal sheets for large burn
wounds [10, 11]. Despite huge progress in cell culture and
discovery of alternative, multi- or pluripotent cell types,
tissue specific, pre-differentiated (lineage-committed) cells
enjoy the attention of the TE field and, for now, are
indispensable as a component of commercially available
TE products (Table 1). Besides fibroblasts, keratinocytes
and chondrocytes, other lineage-committed cells are under
investigation and will soon to be employed in regeneration
or repair of diverse organ/tissue types, including liver [12–
14], bladder [15], kidney [16] and pancreas [17]. However,
due to low proliferative capacity and accessibility, and
insufficient number, primary cells (lineage committed), in
some cases, are not a viable choice. Such limitation can be
by-passed by use of multipotent stem cells, which can give
rise to mesenchymal and non-mesenchymal tissues in vitro
and in vivo. Since the discovery of bone marrow mesen-
chymal stem cells (BMSC) in early 1960s [18] and their
subsequent characterization [19–21], there has been con-
tinual enthusiasm about the possibilities offered by this
type of cells. However, derivation of BMSC requires an
invasive procedure. Moreover, with age, differentiation and
proliferative potential of BMSCs decline [22, 23]. There-
fore, alternative sources from which to isolate multipotent
stem cells have been subject to intensive investigation.
Among the alternative mesenchymal stem cell sources the
most promising are muscles [24], blood [25], placenta [26],
amnion [27], umbilical cord blood [28], umbilical cord [29]
and adipose tissue [30, 31]. The last seems to be a superior
source of stem cells, with greater yield and availability than
bone marrow [32]. The unique properties of mesenchymal
stem cells, especially their immunosuppressive effect, led
to rapid implementation of stem cell clinical trials for a
broad spectrum of conditions [33, 34]. Even more is
expected from pluripotent stem cells, which have a higher
level of plasticity and therefore, a greater potential for
diverse applications. Another cell type, embryonic stem
cells—ESC [35, 36] discovered in the early 1980s, are
controversial because their derivation has been associated
with destruction of an early embryo.
Fortunately, the generation of induced pluripotent stem
cells (iPS) [37] from somatic cells of human origin has
brought forth another potential source of stem cells for TE,
cellular therapies and, what seems to be at our fingertips,
drug development. The efficiency of obtaining iPS cells is
not satisfactory as yet and much effort is still required to
use iPS in practice [38]. Still, stem cells obtained by
methods free from ethical objections can now be seen on
the horizon [39, 40].
Returning to the challenge of engineering a human arm,
we propose using autologous, multipotent, so-called adult
stem cells, which may be obtained via a minimally invasive
procedure, for example, from adipose tissue. At the same
time, we look toward use of multipotent iPS in the future.
In order to obtain a functional tissue or organ, the cells
should undergo differentiation, so that cells of various
phenotypes will meet in a single complex system. There
are well-documented reports that show that a co-culture is
both feasible and effective.
In particular, vascularization of graft might be enhanced
by a combination of endothelial cells with osteogenic [41–
43] or mesenchymal stem/stromal cells [44–47]. Addi-
tionally, endothelial cells may support osteoblast prolifer-
ation [48]. Successful osteoblast-osteoclast cell co-culture
enabling beneficial cross-talk between those two cell
types were also reported [49, 50]. Coexistence of both cell
types is necessary for balanced bone remodeling in order to
ensure structural integrity. Closely related with osteoclasts
are monocytes/macrophages. Their effect on osteogenesis
and application in TE is currently being investigated in co-
culture with bone marrow stem/stromal cells [51]. Suc-
cessful limb regeneration may also include reconstruction
of osteochondral structures. It has been demonstrated that
osteoblasts and chondrocytes influence each other’s biol-
ogy leading to improved, complex and clinically relevant
bone tissue replacement [52–54].
Obviously, the common culture system for the whole
arm will be extremely complex. Regardless of the
demanding shape and size of the whole bio-device, a
separate issue is that the cells of various phenotypes must
be put into the common system. Clearly, culture medium
preferences, which may be significantly different for the
different types of cells needed to regrow a human arm,
would not all be addressed under such conditions. Here, we
would look to the physicochemical characteristics of the
scaffold materials to provide the appropriate cues for
regenerative support.
4 Significant/substantial role of mechanical factors
There is convincing evidence of a significant effect of
substrate stiffness on cell fate. Cell reaction to the rigidity
of a support in culture was documented in 1997, when cell
spreading, migration and cytoskeletal organization of
fibroblasts on polyacrylamide gels of various stiffness was
found to vary [55]. Intriguing data showing differentiation
of MSCs isolated from bone marrow to three different
phenotypes, i.e., neural, osteogenic and myogenic,
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depending only on the stiffness of the culture substrate
without any biochemical stimulation, were published in
Cell in 2006 [56]. This finding opens new possibilities for
complex constructions such as a whole limb. Progenitor
cells seeded on particular parts of the TE construct, having
different mechanical characteristics, might receive differ-
ent signals appropriate for the desired differentiation
without exposure to regulatory molecules. This is of crucial
importance when the cells of various final/endpoint phe-
notypes are cultured in a common culture system, i.e., in
the same biochemical environment. In addition to the
physicochemical characteristics of the biomaterials scaf-
folds supporting the cells, mechanical inputs will be cen-
trally important for developing the different tissue types.
Mechanical training of tissues being cultured in vitro
offers another even more promising possibility. Examples
of very well organized ligament structure obtained in a
culture of bone marrow cells exposed to a cyclic, well
controlled mechanical stimulation were shown by the
Kaplan group [57]. Tenogenesis of MSC in response to
mechanical stimulation was confirmed also by others [58,
59]. At the same time cyclic mechanical stimulation pro-
motes proliferation and function of smooth muscle cells
distributed in 3D scaffolds [60, 61], it may also promote
organization of blood vessels in a complex multi-tissue
structure.
Promotion of osteoblasts differentiation in response to
cyclic mechanical loading applied in vitro has been
reported in the Dynacell culture system with the substrate
subjected to deformation [62, 63] and being in contact with
implantable materials [64]. Also, osteoblast differentiation
was recently reported in 3D systems in which cells were
cultured on scaffolds in bioreactors [65–67]; these studies
were performed on various scaffolds, including partially
demineralized bone matrix [67], fibrin matrix [66] or
poly(L-lactic acid) porous scaffolds [65]. They were also
performed under different mechanical conditions.
Mechanically promoted osteogenic stimulation was
achieved in all those situations regardless of the experi-
mental system details. Such findings justify including
mechanical stimulation in bone regeneration strategies.
In addition to formation of tendons, ligaments and bone-
like tissue in vitro, under applied mechanical forces, tissue
engineered cartilage has been obtained under complex
mechanical loading [68, 69]. In the case of cartilage,
combined compression-shear stimulation was found to be
more effective than simple loading [69]. Obtaining carti-
lage under such conditions was documented not only in
culture of animal chondrocytes [68] but also in human
MSC culture [69].
Mechanical training, which seems beneficial for matu-
ration and organization of single tissues or tissue-like
structures, will be critical for the whole organ. Convincing
data showing the significance of cells exercising in vitro for
the functionality of the engineered ex vivo bladder are
widely known. Obviously, creating the whole human arm
in vitro is much more complicated, but not impossible. The
brief review given in this paper shows that the necessary
tools are already available. We also have access to a wide
array of cytocompatible biomaterials representing a broad
spectrum of mechanical characteristics. They can be used
for the construction of the particular tissues and structures
of the human arm and at the same time may serve as
temporary scaffolds for cells. Multipotent autologous cells
may be obtained via minimally invasive surgery, e.g., from
adipose tissue. Their phenotype and function may then be
regulated by both physicochemical characteristics of the
scaffold and exposure to mechanical training. We have
shown here that cells not only tolerate but also respond in a
controlled manner to the dynamic conditions of culture in
various types of bioreactors. The cells also tolerate co-
culture systems, which make possible the construction of
organs consisting of cells of various phenotypes. As a
result the required tissues may be obtained in vitro due to
the responses of the patient’s own cells under the condi-
tions applied to the system.
The mechanical system that simulates the activity and
range of motion of the human arm is not necessarily very
difficult to obtain. In one of the experiments from the
Kaplan group, cells were exposed to mechanical stimula-
tion within an Instron Material Tester [67]. Much more
complicated systems dedicated to testing orthopaedic
endoprosthesis and conducting orthopaedic kinematics
studies under several degrees of freedom are commercially
available. They enable using a combination of various
types of loading and motions that simulate physiological
activity. Such devices for fatigue tests provide a possibility
of prolonged observation in a wet environment and might
be a perfect basis for constructing a bioreactor for human
arm manufacturing in vitro.
5 To sum up
The ability to create a full and functional autogenic human
limb in an ex vivo bioreactor seems a futuristic dream
today. However, reports of the very promising possibilities
of engineering tissues in various experimental systems
justify our expectation that the goal of a tissue-engineered
arm may be reached. Smart, well-characterized biomaterial
scaffolds which may influence cells’ fate in a controlled
manner, and endogenous extracellular matrix produced by
a co-cultured mix of a patient’s own cells and organized
under mechanical control in a bioreactor, are suitable tools
to make the sophisticated puzzle pieces of an autologous
human arm engineered in vitro. We have these tools partly
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at hand and partly on the near horizon. Perfectly orches-
trated collaboration of top class scientists in an interdisci-
plinary team is indispensable for a successful outcome. In
this paper, we strongly emphasize the added value coming
from mechanical activation of engineered tissues, which
still seems underestimated. Obviously, transferring the
promising results from small culture systems to the scale of
the whole limb, including the particular difficulty in mak-
ing interfaces with nerves or blood vessels, will be extre-
mely demanding. Preparing the engineered tissues for
anastomose with the appropriate parts of the host tissues
via sophisticated surgery would be also challenging.
However, examples of spectacular complex surgical pro-
cedures, like face transplantation are encouraging in this
respect [70]. On the other hand, preparation for the first
face transplant by Siemionow took about 20 years. Defi-
nitely, we should be very careful in determining the time
horizon for producing a live human limb in vitro. We
believe that a prototype construction might be realistically
achievable within some 20 years. The way from a proto-
type to the GMP clinically approved technology has to be
even longer. Improving the bench-to-bedside pathway is a
well-recognized challenge [71, 72]. Therefore, we may
expect that new solutions in this area will be elaborated in
parallel to the experimental work on regrowing a human
arm in vitro. Altogether, we think that hard scientific data
and technological possibilities already offered by TE or
seen on the horizon justify planning ambitious goals like
regeneration of the human arm. Such challenges in turn
stimulate further progress in regenerative medicine.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
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